Sinopharm Group Co Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHTDF vs MCK, COR, CAH: Buyback Yield % Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co Buyback Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co (SHTDF) has a Buyback Yield % of 0.00 as of Jun. 25, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Sinopharm Group Co and its competitors. According to the industry distribution chart, Sinopharm Group Co ranks #999999 out of 37 companies in the Medical Distribution industry.
Is Sinopharm Group Co's Buyback Yield % too high?
Sinopharm Group Co's current Buyback Yield % is 0.00. Based on the distribution chart, Sinopharm Group Co ranks #999999 out of 37 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Sinopharm Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Buyback Yield % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #999999 out of 37 companies for Buyback Yield %. This places Sinopharm Group Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Distribution company?
A good Buyback Yield % depends on the Medical Distribution industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Sinopharm Group Co and its competitors. Sinopharm Group Co's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.78, compared to a current price of $2.29 — trading 17.7% below its estimated fair value. The current Buyback Yield % is 0.00. Sinopharm Group Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current Buyback Yield % is 0.00 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.29 is trading 17.7% below its estimated GF Value™ of $2.78.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
Buyback Yield %: 0.00
GF Value™: $2.78 vs. price of $2.29 (17.7% below fair value)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
78GF Score
Get the complete analysis for SHTDF
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
